You are here: Welcome to the MPKB » Welcome to the MPKB » Non-MP therapies » Anti-TNF drugs
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:othertreatments:antitnf [11.02.2009] – marysuehome:othertreatments:antitnf [05.02.2011] – external edit 127.0.0.1
Line 1: Line 1:
 ====== Anti-TNF drugs ====== ====== Anti-TNF drugs ======
  
-<html><div class="mainarticle">Related article:</html> [[home:patients:assessing_literature:palliative|Palliative vs. curative treatments]] <html></div></html>+<relatedarticle> [[home:patients:assessing_literature:palliative|Palliative vs. curative treatments]] </article>
  
  
Line 30: Line 30:
 ==== Olmesartan (Benicar) vs. TNF-alpha blockers ==== ==== Olmesartan (Benicar) vs. TNF-alpha blockers ====
  
-<html><div class="mainarticle">Related article:</html> [[home:protocol:olmesartan:safety|Olmesartan safety]]  <html></div></html>+<relatedarticle> [[home:protocol:olmesartan:safety|Olmesartan safety]]  </article>
  
  
Line 65: Line 65:
 To reduce the likelihood of contracting or exacerbating tuberculosis, prospective patients are routinely tested for infection via a skin test. However, as some researchers have noted, TB skin tests on patients treated with immunosupressants, which are routinely used on rheumatoid arthritis patients, are not reliable, because they result in false negatives.(({{pubmed>long:12614731}})) To reduce the likelihood of contracting or exacerbating tuberculosis, prospective patients are routinely tested for infection via a skin test. However, as some researchers have noted, TB skin tests on patients treated with immunosupressants, which are routinely used on rheumatoid arthritis patients, are not reliable, because they result in false negatives.(({{pubmed>long:12614731}}))
  
-Fatal fungal infections have been noted. In 2008, the FDA [[http://www.fda.gov/CDER/drug/InfoSheets/HCP/TNF_blockersHCP.htm|ordered stronger warnings]] on Enbrel, Remicade, Humira and Cimzia due to increased risk of these infections.+"Exaggerated //Borreliosis// infections" have been noted(({{pubmed>long:20184613}})) as have been fatal fungal infections. In 2008, the FDA [[http://www.fda.gov/CDER/drug/InfoSheets/HCP/TNF_blockersHCP.htm|ordered stronger warnings]] on Enbrel, Remicade, Humira and Cimzia due to increased risk of fungal infections.
  
 Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus.
home/othertreatments/antitnf.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.